Market cap
$6.4bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
Amtagvi ® has multiple growth drivers, including: Proleukin ® We sell Proleukin ® (aldesleukin), an interleukin-2, or IL-2, product to three main distributors in the U.S., distributors outside the U.S., and numerous third-party clients across the three revenue channels: 1) use in the Amtagvi ® treatment regimen, or other approved oncology uses, or the primary channel, 2) use in the manufacturing process for Amtagvi ® and other cell therapies and 3) use in clinical and research settings. The increase in revenue as compared to the prior period was driven by an increase in Amtagvi ® infusions, correspondent increase in Proleukin ® , and price increases for both products. …IOVANCE BIOTHERAPEUTICS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06